In July, India’s domestic pharma retail market experienced an 11% growth, driven by sales of anti-infectives and pain-relief medicines due to increased flu and viral infections. Augmentin emerged as the top-selling brand with Rs 72 crore in sales. Acute therapies, including pain and anti-infectives, grew by 11%, while chronic medications increased by 12%.
Related Posts
Budget 2025-26: CII calls for cut in excise duty on fuel, consumption vouchers to stir demand
The Confederation of Indian Industry (CII) recommends reducing excise duty on fuel and lowering personal income tax rates to boost consumption and tackle inflation. CII […]
UltraTech Cement gets CCI’s clearance to acquire majority stake in India Cements
Competition Commission of India (CCI) has approved UltraTech Cement’s acquisition of a majority stake in India Cements. UltraTech will acquire a 32.72% stake from promoters […]
Budget 2025: Rent a home or buy one? That’s a yuge dilemma
- staff
- February 2, 2025
- 0
Deciding between renting and buying a home is complex. Renting offers flexibility and potential tax advantages under the old tax regime but lacks the long-term […]